Adia Med CEO Larry Powalisz Issues Open Letter on Leadership Journey, Research Mission, and Progress Since 2024

The update pairs a $1.5 million subsidiary stake sale with full repayment of the related-party credit facility.

Rhea-AI Summary

Adia Med (OTCQB: ADIA) released CEO Larry Powalisz’s open letter reviewing its regenerative medicine business and research progress since January 2024. The company opened its Winter Park clinic, beginning operations and initial patient treatments in January 2025, and attained full SEC reporting status in February 2026.

Adia Med sold a 30% stake in Adia Labs for $1.5 million through its partnership with Live Oak Health, doing business as QCM Biologics, and fully repaid its related-party credit facility. Powalisz separately purchased a 7% economic interest in Adia Labs for $350,000. An autism study began treating its first cohort in May 2026; interim safety data showed no serious adverse events, without establishing efficacy or overall safety. The company plans clinic and distribution expansion, additional studies and a Nasdaq Capital Market uplisting, and has engaged specialized counsel for the uplisting.

13 points · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointAdia Labs’ 30% stake sale for $1.5 million accompanied the partnership with QCM Biologics. 13% of market cap
• Moderate pointThe related-party credit facility was fully repaid.
• Moderate pointRevenue grew, driven primarily by biologics sales and clinical procedures.
• Moderate pointThe Winter Park clinic began operations and initial patient treatments in January 2025.
• Minor pointForm 10 effectiveness brought full SEC reporting status in February 2026, following the OTCQB uplisting.

8 minor points

• Minor pointThe autism study’s first cohort began treatment in May 2026 using AdiaVita with glutathione.
• Minor pointAutism study interim safety data showed no serious adverse events; this does not establish efficacy or overall safety.
• Minor pointInstitutional review board-approved studies also address chronic kidney disease and lower back pain.
• Minor pointBiologic inventory grew to an estimated retail value of $1.5 million.
• Minor pointAdia Life was created as a dedicated distribution entity.
• Minor point. Forward-looking: it has not happened yet and may not happen.Clinic-network and distribution-partnership expansion are planned.
• Minor point. Forward-looking: it has not happened yet and may not happen.Additional studies in COPD and osteoarthritis are planned.
• Minor point. Forward-looking: it has not happened yet and may not happen.The planned Nasdaq Capital Market uplisting has specialized counsel engaged; the company exceeds Nasdaq’s round-lot holder threshold.

Negative

• None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Winter Park, Florida--(Newsfile Corp. - November 9, 2026) - Adia Med Inc. (OTCQB: ADIA) today released the following open letter from Chief Executive Officer Larry Powalisz outlining the company's progress since the January 2024 leadership transition, its regenerative medicine research mission, and efforts to generate evidence that could support broader access to investigational therapies.

An Open Letter from Larry Powalisz, CEO of Adia Med Inc.

November 5, 2026
Winter Park, Florida

To Our Stakeholders, Patients, Physicians, and Friends:

When I became CEO of what was then Adia Nutrition Inc. in January 2024, the company was largely inactive. I took control through Legends Investments Properties, LLC with a clear purpose: to help build a regenerative medicine platform that raises awareness of the field's potential and generates research evidence that could, over time, support insurance coverage decisions for eligible treatments, while also establishing revenue-generating operations through biologics manufacturing and sales, clinic-based clinical procedures, and distribution partnerships. Our goal is to broaden access for people who cannot afford out-of-pocket costs. This remains our mission today.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/322882_1.jpg

My interest in this work is personal. I was diagnosed with Primary Progressive Multiple Sclerosis in June 2021 at age 57. I experienced left-side paralysis, severe brain fog, and drop foot that made walking difficult. My neurologist projected I would be in a wheelchair within three to five years. Before treatment, I had 20 lesions in my brain, including 10 active lesions, and one lesion in my spinal cord. After researching options, I traveled to Mexico for hematopoietic stem cell transplantation approximately four and a half years ago. Following treatment, I report that disease progression halted, my paralysis resolved, my brain fog substantially improved, and I entered remission. I also report no new lesions and no further lesion activity since treatment. Years later, I continue to walk independently with mild residual drop foot. My individual experience does not establish treatment effectiveness or predict outcomes for other patients.

I subsequently founded the nonprofit MS Heal the World to support people pursuing HSCT globally. When I redirected Adia Med toward regenerative therapies—particularly allogeneic umbilical cord blood-derived stem cells and exosomes—I did so with the aim of expanding domestic research access. I personally funded early operations through credit facilities.

Since the January 22, 2024 leadership transition, we have advanced from a dormant entity to an active regenerative medicine platform. We formed Adia Med of Winter Park, LLC and Adia Labs LLC; leased and opened our flagship Winter Park clinic, where operations and initial patient treatments began in January 2025; secured biologics manufacturing we describe as FDA-compliant; uplisted to the OTCQB Venture Market; and achieved full SEC reporting status when our Form 10 registration became effective in February 2026. We divested non-core assets, retired improperly issued shares, and developed a pipeline of IRB-approved studies.

These include a pediatric autism spectrum disorder study (NCT07304440) using AdiaVita combined with glutathione, with the first cohort beginning treatment in May 2026. Recent interim safety data showed no serious adverse events; that interim observation does not establish efficacy or overall safety. Other studies address chronic kidney disease and lower back pain, with additional protocols planned.

We have also reported substantial revenue growth driven primarily by biologics sales and clinical procedures. In 2026, we completed our name change to Adia Med Inc., expanded the Adia Labs product line, created Adia Life LLC as our dedicated distribution entity, and partnered with Live Oak Health (d/b/a QCM Biologics), including a 30% stake sale in Adia Labs for $1.5 million. We fully repaid our related-party credit facility. I personally purchased a 7% economic interest in Adia Labs for $350,000.

Patients may be considered for participation in a group study or an individualized, single-patient study designed around their particular medical condition and needs. Participation depends on study availability, physician assessment, eligibility requirements, applicable regulatory and institutional review board (IRB) approvals, and informed consent. An individualized study is an investigational research approach, not a guarantee of treatment access or benefit. Patients and referring physicians interested in current research opportunities may contact us at ceo@adiamed.com or 321-231-2843 to request study information and eligibility screening. An inquiry does not establish eligibility or guarantee enrollment.

Under our current structure, Adia Labs focuses on product development and manufacturing and sells exclusively to master distributors (including QCM Biologics and Adia Life LLC). Adia Life LLC sells products directly to physicians. Adia Labs' current product portfolio includes:

• AdiaVita – Formulated with 50 million stem cells/TNCs and 1 trillion exosomes.
• AdiaLink – An exosome product formulated with 3 trillion exosomes.
• Adia30M – A stem cell product formulated with 30 million stem cells/TNCs.
• AdiaExo – An exosome product formulated with 1 trillion exosomes.
• AdiaClear – An exosome product available in eye-drop and ear formulations.

Adia30M

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/322882_adia30m.jpg

Our clinical services include orthopedic treatments, pain management, and wound repair, alongside umbilical cord blood-derived stem cell therapies, platelet-rich plasma (PRP), and therapeutic plasma exchange (TPE). We are not currently offering HSCT/aHSCT. Our biologic inventory has grown to an estimated retail value of $1.5 million to meet demand. We exceed Nasdaq's round-lot holder threshold and have engaged specialized counsel, Lucosky Brookman LLP, to advance a planned uplisting from the OTC Markets to the Nasdaq Capital Market.

Looking ahead, we plan to advance our clinical studies, scale our clinic network and distribution partnerships, expand our study pipeline to additional indications such as COPD and osteoarthritis, and continue product innovation in cell count, format, and concentration. These efforts support our mission to raise awareness of regenerative medicine's potential and generate evidence that could inform insurance companies' coverage decisions, reduce the out-of-pocket burden of eligible treatments, and help people who otherwise could not afford care. Insurance coverage remains a long-term objective, not a current promise or guaranteed outcome.

We also plan to complete the Nasdaq uplisting process. We have only just begun and remain focused on meaningful clinical and operational progress and long-term value.

For investors, our long-term objective is to build sustainable shareholder value through the research, clinic expansion, distribution partnerships, and product development initiatives described above. These plans represent strategic objectives, not guarantees of financial performance, share-price appreciation, or investment returns.

Thank you for your interest and support. Questions or inquiries may be directed to me at ceo@adiamed.com or 321-231-2843.

Sincerely,
Larry Powalisz
Chief Executive Officer
Adia Med Inc. (OTCQB: ADIA)

About Adia Med Inc.

Adia Med Inc. (OTCQB: ADIA), headquartered in Winter Park, Florida, is a regenerative medicine company focused on physician-supervised care and investigational research. Its clinics offer orthopedic treatments, pain management, and wound repair, alongside stem cell therapies, platelet-rich plasma (PRP), and therapeutic plasma exchange (TPE). The company is not currently offering HSCT/aHSCT. Its IRB-approved studies target autism spectrum disorder, chronic kidney disease, and lower back pain, with more planned. Its Adia Labs division manufactures regenerative products, including AdiaVita and AdiaLink, that support this clinical work. The company's research mission includes raising awareness of potential applications and developing evidence that could support broader insurance coverage and access for patients facing affordability barriers.

Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co

Twitter (X): @adia_med
Instagram: @adia_med
Facebook: @adia_med

Research and Study Only Disclaimer

The investigational products and applications discussed in connection with the studies described in this release are for research and study purposes only. References to potential benefits, personal experiences, or preliminary observations do not establish safety or effectiveness and do not constitute claims that an investigational product diagnoses, treats, cures, or prevents any disease. This release is informational only and is not medical advice or a substitute for consultation with a qualified healthcare professional. Study participation is subject to the applicable protocol, eligibility requirements, and informed consent. Outcomes and future insurance coverage are not guaranteed.

Safe Harbor

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/322882

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were the terms of Adia Med’s Adia Labs stake transactions?

A 30% stake in Adia Labs was sold for $1.5 million as part of the partnership with Live Oak Health, doing business as QCM Biologics. Separately, CEO Larry Powalisz personally purchased a 7% economic interest for $350,000.

What did Adia Med report from its autism study?

Interim safety data showed no serious adverse events, but that observation does not establish efficacy or overall safety. The pediatric autism spectrum disorder study, NCT07304440, uses AdiaVita combined with glutathione, and its first cohort began treatment in May 2026.

How do Adia Labs and Adia Life distribute Adia Med’s products?

Adia Labs sells exclusively to master distributors, including QCM Biologics and Adia Life. Adia Labs focuses on product development and manufacturing, while Adia Life sells products directly to physicians.